Gregory Jackson, MD
Advanced Heart Failure and Transplant Cardiology · Charleston, SCNPI 1518284843
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $2,500 of the $3,770 with a category attached, or 66.3%. ZOLL Respicardia, Inc. accounts for 66.3% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2021 at $2,548 and has fallen 77.0% since, to $586 in 2025. That places this record below the midpoint for advanced heart failure and transplant cardiology clinicians in SC, where the typical reported total is $13,902.
Across 20 payments — averaging $188.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ZOLL Respicardia, Inc.$3K
- Cvrx, Inc.$304
- Abiomed$273
- Endotronix, Inc.$271
- Abbott$214
- Medtronic$155
- plus $54 from 2 others
Across 21 payments — averaging $17,873 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$342K
- AstraZeneca$33K
What the payments were for
- Speaking & faculty fees$2,50066%
- Food & beverage$1,27034%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ZOLL Respicardia, Inc. | 1 | $2,500 |
| Cvrx, Inc. | 5 | $304 |
| Abiomed | 3 | $273 |
| Endotronix, Inc. | 1 | $271 |
| Abbott | 6 | $214 |
| Medtronic | 2 | $155 |
| Itamar Medical Inc | 1 | $30 |
| Briohealth Solutions, Inc. | 1 | $25 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,770 in reported general payments places this provider in the 20th percentile of 30 advanced heart failure and transplant cardiology providers in South Carolina.
See all advanced heart failure and transplant cardiology providers in South Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 161 | $225,648 |
| FarxigaDapagliflozin Propanediol | 65 | $86,515 |
| JardianceEmpagliflozin | 74 | $80,508 |
| EliquisApixaban | 67 | $59,552 |
| XareltoRivaroxaban | 14 | $22,343 |
| Bumetanide | 34 | $2,328 |
| Metoprolol Succinate | 101 | $1,473 |
| Spironolactone | 106 | $859 |
| Carvedilol | 101 | $689 |
| Atorvastatin Calcium | 44 | $509 |
| Furosemide | 120 | $489 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 31 | $438 |
| Losartan Potassium | 40 | $388 |
| Potassium Chloride | 16 | $384 |
| Nitroglycerin | 21 | $337 |
Paid to pharmacies, not to this prescriber.
Other advanced heart failure and transplant cardiology in Charleston
- Ryan TedfordCharleston$528K
- Michael ZileCharleston$358K
- Daniel JudgeCharleston$116K
- Ramsey WehbeCharleston$108K
- Sheldon LitwinCharleston$86K
- Brian HoustonCharleston$43K
- Jan GriffinCharleston$23K
- Adrian VanbakelCharleston$21K
- Daniel SilvermanCharleston$11K
- Vishal RaoCharleston$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.